RxDoctor Payments Data

Chau Nguyen, DO

Internal Medicine · Georgetown, TXNPI 1396197661

Payments from drug & device makers

$1,491in general payments, 2019–2025

Across 70 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$344
  • AbbVie$211
  • Novo Nordisk$180
  • Dexcom, Inc.$159
  • Lilly USA, LLC$146
  • Johnson & Johnson$138
  • plus $313 from 8 others

What the payments were for

  • Food & beverage$1,47999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,491 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,003
Medicare patients
251
Services billed
1,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$69,236
RybelsusSemaglutide25$55,522
JanuviaSitagliptin Phosphate20$31,806
JardianceEmpagliflozin16$28,594
FarxigaDapagliflozin Propanediol21$23,990
OzempicSemaglutide21$21,679
EliquisApixaban17$19,739
VemlidyTenofovir Alafenamide12$17,395
Advair HfaFluticasone Propion/Salmeterol12$6,459
Lidocaine28$3,934
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,649
Albuterol Sulfate HfaAlbuterol Sulfate76$2,407
Levothyroxine Sodium231$2,370
Gabapentin146$2,064
Atorvastatin Calcium287$1,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$180$77,20146 claims
Lilly USA, LLCMounjaro$146$69,23654 claims
Boehringer IngelheimJardiance$76$28,59416 claims
AstraZenecaFarxiga$344$23,99021 claims
PfizerEliquis$16$19,73917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →